Cost-effectiveness of chronic hepatitis C screening and treatment
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence increases with age. The anti-HCV antibody test, which is cheaper than the HCV RNA assay, is widely used to screen for HCV infections; however, the underdiagnosis of HCV is a major barrier to the elimination of HCV infections. Although several risk factors have been associated with HCV infections, including intravenous drug use, blood transfusions, and hemodialysis, most patients with HCV infections present with no identifiable risk factors. Universal screening for HCV in adults has been suggested to improve the detection of HCV infections. We reviewed the cost-effectiveness of HCV screening and the methodologies used to perform screening. Recent studies have suggested that universal HCV screening and treatment using direct-acting antivirals represent cost-effective approaches to the prevention and treatment of HCV infection. However, the optimal timing and frequency of HCV screening remain unclear, and further studies are necessary to determine the best approaches for the elimination of HCV infections.
Abstract
Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence increases with age. The anti-HCV antibody test, which is cheaper than the HCV RNA assay, is widely used to screen for HCV infections; however, the underdiagnosis of HCV is a major barrier to the elimination of HCV infections. Although several risk factors have been associated with HCV infections, including intravenous drug use, blood transfusions, and hemodialysis, most patients with HCV infections present with no identifiable risk factors. Universal screening for HCV in adults has been suggested to improve the detection of HCV infections. We reviewed the cost-effectiveness of HCV screening and the methodologies used to perform screening. Recent studies have suggested that universal HCV screening and treatment using direct-acting antivirals represent cost-effective approaches to the prevention and treatment of HCV infection. However, the optimal timing and frequency of HCV screening remain unclear, and further studies are necessary to determine the best approaches for the elimination of HCV infections.
참고문헌 (43)
- World Health Organization (WHO), "Progress report on HIV, viral hepatitis and sexually transmitted infections 2019: accountability for the global health sector strategies, 2016–2021", Geneva: WHO (2019)
- Sarin SK, "Liver diseases in the Asia-Pacific region : a Lancet Gastroenterology & Hepatology Commission", Lancet Gastroenterol Hepatol, 5, pp.167~228 (2020)
- Sang Soo Lee, "Type and cause of liver disease in Korea: single-center experience, 2005-2010", Clinical and Molecular Hepatology, 18(3), pp.309~315 (2012), 대한간학회[DOI]
- Wong MCS, "The changing epidemiology of liver diseases in the Asia-Pacific region", Nat Rev Gastroenterol Hepatol, 16, pp.57~73 (2019)
- Kyung-Ah Kim, "Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey", Gut and Liver, 14(5), pp.644~651 (2020), 거트앤리버 소화기연관학회협의회[DOI]
- Kim DY, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)
- Kim BK, "Current status of and strategies for hepatitis C control in South Korea", Clin Mol Hepatol, 23, pp.212~218 (2017)
- Eun Sun Jang, "The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015", Hepatology International, 13(5), pp.599~608 (2019), Springer Science and Business Media LLC[DOI]
- Kim DY, "Costeffectiveness of increased screening and treatment of chronic hepatitis C in Korea", Curr Med Res Opin, 36, pp.993~1002 (2020)
- 김종엽, "Behavioral and Healthcare-Associated Risk Factors for Chronic Hepatitis C Virus Infection in Korea", Journal of Korean Medical Science, 27(11), pp.1371~1377 (2012), 대한의학회
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea : a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)
- El Khoury AC, "Economic burden of hepatitis C-associated diseases in the United States", J Viral Hepat, 19, pp.153~160 (2012)
- Westbrook RH, "Natural history of hepatitis C", J Hepatol (2014)
- Alborino F, "Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity", Med Microbiol Immunol, 200, pp.77~83 (2011)
- Stepanova M, "Economic burden of hepatitis C infection", Clin Liver Dis, 21, pp.579~594 (2017)
- McAdam-Marx C, "All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States : a managed care perspective", J Manag Care Pharm, 17, pp.531~546 (2011)
- Razavi H, "Chronic hepatitis C virus(HCV)disease burden and cost in the United States", Hepatology, 57, pp.2164~2170 (2013)
- 기모란, "Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data", Gut and Liver, 11(6), pp.835~842 (2017), 거트앤리버 소화기연관학회협의회
- Kim DY, "Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea", Medicine(Baltimore), 95, pp.e3896~ (2016)
- Choi Gwang Hyeon, "A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea", Gut and Liver, 14(6), pp.808~816 (2020), 거트앤리버 소화기연관학회협의회[DOI]
- Schillie S, "CDC recommendations for hepatitis C screening among adults-United States, 2020", MMWR Recomm Rep, 69, pp.1~17 (2020)
- Drummond MF, "Methods for the economic evaluation of health care programmes" (2015), Oxford University Press
- McIntosh E, "Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science", Pharmacoeconomics, 15, pp.357~367 (1999)
- Robinson R, "Cost-effectiveness analysis", BMJ, 307, pp.793~795 (1993)
- Torrance GW, "Utilities and quality-adjusted life years", Int J Technol Assess Health Care, 5, pp.559~575 (1989)
- Briggs A, "An introduction to Markov modelling for economic evaluation", Pharmacoeconomics, 13, pp.397~409 (1998)
- Kim DY, "Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea", PLoS One, 12, pp.e0167770~ (2017)
- Kim KA, "Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population", Liver Int, 39, pp.60~69 (2019)
- Kim J, "Cost-effectiveness of scaling up of hepatitis C screening and treatment : a modelling study in South Korea", BMJ Glob Health, 4, pp.e001441~ (2019)
- Centers for Disease Control, "Locations and reasons for initial testing for hepatitis C infection--chronic hepatitis cohort study, United States, 2006-2010", MMWR Morb Mortal Wkly Rep, 62, pp.645~648 (2013)
- Rein DB, "The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U. S. primary care settings", Ann Intern Med, 156, pp.263~270 (2012)
- "Surveillance for Viral Hepatitis – United States, 2011"[URL]
- Havens PL, "Updated CDC recommendations for universal hepatitis C virus screening among adults and pregnant women : implications for clinical practice", JAMA, 323, pp.2258~2259 (2020)
- Eckman MH, "Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens", Clin Gastroenterol Hepatol, 17, pp.930~939 (2019)
- Higuchi M, "Epidemiology and clinical aspects on hepatitis C", Jpn J Infect Dis, 55, pp.69~77 (2002)
- Nakamura J, "Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups", Tohoku J Exp Med, 215, pp.33~42 (2008)
- Nagai K, "Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan", Hepatol Res, 50, pp.542~556 (2020)
- Sroczynski G, "Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection", Eur J Public Health, 19, pp.245~253 (2009)
- Harris RJ, "Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data", J Viral Hepat, 26, pp.541~551 (2019)
- Williams J, "Cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the national health service health check program in England", Value Health, 22, pp.1248~1256 (2019)
- Deuffic-Burban S, "Assessing the cost-effectiveness of hepatitis C screening strategies in France", J Hepatol, 69, pp.785~792 (2018)
- Wong WWL, "Cost-effectiveness of screening for hepatitis C in Canada", CMAJ, 187, pp.E110~E121 (2015)
- World Health Organization(WHO), "Draft global health sector strategy on viral hepatitis, 2016-2021", WHO, ~ (2016)